Preoperative Concomitant Radiochemotherapy with A 5-Fluorouracil plus Folinic Acid Bolus in the Combined Treatment of Locally Advanced Extraperitoneal Rectal Cancer: A Long-Term Analysis on 27 Patients
Restricted accessResearch articleFirst published online March, 2003
Preoperative Concomitant Radiochemotherapy with A 5-Fluorouracil plus Folinic Acid Bolus in the Combined Treatment of Locally Advanced Extraperitoneal Rectal Cancer: A Long-Term Analysis on 27 Patients
Many studies of preoperative chemoradiation in resectable rectal cancer have focused on downstaging and sphincter-saving procedures. The aim of this study was to evaluate long-term outcome in resectable rectal cancer treated with preoperative chemoradiation and surgery by only one surgical team irrespective of the tumor downstaging.
Material and methods
From 1992 to 2001, in a cooperative study between the Institute of Semeiotica Chirurgica and the Division of Radiotherapy of the Catholic University of the Sacred Heart, 27 patients with locally advanced rectal cancer were treated with preoperative chemoradiation, followed by surgery after 4-6 weeks, and, just for 6 of them, by adjuvant chemotherapy. Seventeen patients were staged T3 N1 (63%), 4 patients T3N0 (15%), 4 patients T3N2 (15%) and 2 T4N2 (7.5%). Twenty-three patients (85.1%) had signs of nodal involvement at combined imaging. Radiation therapy was delivered to the posterior pelvis at a dose of 45 Gy to the tumor (clinical target volume) and the whole pelvis (planning target volume). Fractionation was conventional: 1.8 Gy/day, 5 fractions a week. Radiotherapy was started on Monday for all patients and was delivered with a linear accelerator. Concomitant chemotherapy consisted of 5-fluorouracil (350 mg/m2/day, as an intravenous bolus on days 1-5 and 29-33 of radiotherapy) and folinic acid (L-isomer) (10 mg/m2 as an intravenous bolus on days 1-5 and 29-33). This chemotherapy was generally administered about 1 hr before radiotherapy. Data were analyzed on July 2002; median follow-up was 59 months (range, 20-116 months). No patient was lost during the follow-up.
Results
All patients completed the treatment. Grade >3 acute toxicity occurred in 11% of the patients and late toxicity was 15%. A pathologic complete response was recorded in 22% of patients; sphincter-preserving surgery was feasible in 44%. Seven patients died: 2 of them perioperatively, 1 patient died with local recurrence, and 1 died with distant metastases; 3 patients died during the follow-up for other causes. Five-year local control was 95% and overall survival was 84%.
Conclusions
Our study, although limited in number, demonstrated good results in local control and disease-free survival with a limited toxicity.
De VitaV.T., LippmanM., HubbardS.M., IhdeD.C., RosenbergS.A.: The effect of combined modality therapy on local control and survival.Int J Radiat Oncol Biol Phys,12: 487–501, 1986.
2.
ValentiniV., CocoC., CelliniN., PicciocchiA., FaresM.C., RosettoM.E., MantiniG., MorgantiA.G., BarbaroB., CogliandoloS., NuzzoG., TedescoM., Ambesi-ImpiombatoF., CosimelliM., RotmanM.: Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response and sphincter preservation in three consecutive studies.Int J Radiat Oncol Biol Phys,51: 371–383, 2001.
3.
UICC International Union Against Cancer:TNM classification of malignant tumours, 4th edition, 2nd revision, Springer Verlag, Heidelberg, 1997.
4.
CapirciC., PolicoC., MandolitiG.: Dislocation of small bowel volume within box pelvic treatment fields, using new “Up-Down Table” device.Int J Radiat Oncol Biol Phys,51: 465–473, 2001.
5.
International Commission on Radiation Units and Measurement. ICRU Report 50: Prescribing, recording and reporting photon beam therapy,1993.
6.
MillerA.B., HoogstratenB., StaquetM., WinklenA.: Reporting result of cancer treatment.Cancer,47: 207–214, 1981.
7.
PerezC.A., BradyL.W.: Overview. In: Principles and practice of radiation oncology, PerezC.A., BradyL.W. (Eds), 2nd edition, pp 1–62, Lippincott, Philadelphia, 1992.
RosenthalC.J., RotmanM.: The development of chemotherapy drugs as radiosensitizers: an overview. In: Concomitant continuos infusion chemotherapy and radiation, RotmanM., RosenthalC.J. (Eds), pp 1–9, Spinger Verlag, Berlin, 1991.
11.
VokesE.E., WeichselbaumR.R.: Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors:J Clin Oncol, 8: 911–934, 1990.
12.
ViettiJ., EggerdineF., ValerioteF.: Combined effect of X-radi-ation and 5-FU on survival of transplanted leukemic cells.J Natl Cancer Inst,47: 865–870, 1971.
13.
ByfieldJ.E., FrankelS.S., HornbeckC.L., SharpT.R., CallipariF.B., FloydR.A.: Phase I and pharmacologic study of 72-hour infused 5-fluorouracil and hyperfractionated cyclical radiation.Int J Radiat Oncol Biol Phys,11: 791–800, 1985.
14.
ByfieldJ.E., Calabro-JonesP., KlisakI., KulhanianF.: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X-rays.Int J Radiat Oncol Biol Phys,8: 1923–1933, 1982.
15.
ByfieldJ.E.: Theoretical basis and clinical applications of 5-fluorouracil as a radiosensitizer – an overview. In: Concomitant continous infusion chemotherapy and radiation, RotmanM., RosenthalC.J. (Eds), pp 115–127, Springer Verlag, Berlin, 1991.
16.
SeifertP., BakerL.H., ReedM.L., VaitkeviciusV.K.: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.Cancer,36: 123–128, 1975.
17.
SkibberJ.H., HoffP.M., MinskyB.D.: Cancer.Principles & Practice of Oncology,De VitaV.T., HellmanS., RosenbergS.A. (Eds), 6th edn, pp 1271–1319, Lippincott Williams & Wilkins, Philadelphia, 2001.
18.
Boulis WassifS., GerardA., LoygueJ., CamelotD., BuyseM., DuezN.: Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment on Cancer Gastrointestinal Tract Cancer Cooperative Group.Cancer,53: 1811–1818, 1984.
19.
GITSG 7175:Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group.N Engl J Med, 312: 1465–1472, 1985.
HyamsD.M., MamounasE.P., PetrelliN., RocketteH., JonesJ., WieandH.S., DeutschM., WickerhamL., FisherB., WolmarkN.: A clinical trial to evaluate the worth of preoperative multi-modality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03.Dis Colon Rectum,40: 131–139, 1997.
22.
GITSG 7180:Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.J Clin Oncol,10: 549–557, 1992.
23.
O'ConnellM.J., MartensonJ.A., WieandH.S.: Improving adjuvant therapy for rectal cancer by combined protracted-infusion fluorouracil with radiation therapy after curative surgery.N Engl J Med,331: 502–507, 1994.
MohiuddinM.: Low dose preoperative radiation in the treatment of carcinoma of the rectum.Ann Ital Chir,72: 533–538, 2001.
27.
ValentiniV., CocoC., PicciocchiA., MorgantiA.G., TrodellaL., CiabattoniA., CelliniF., BarbaroB., CogliandoloS., NuzzoG., DogliettoG.B., Ambesi-ImpiombatoF., CosimelliM.: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.Int J Radiat Oncol Biol Phys,53: 664–674, 2002.
28.
ShumateC.R., RichT.A., SkibberJ.M., AjaniJ.A., OtaD.M.: Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity.Cancer,71: 3690–3696, 1993.
29.
ChariR.S., TylerD.S., AnscherM.S., RussellL., ClaryB.M., HathornJ., SeiglerH.F.: Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum.Ann Surg,221: 778–786, 1995.
30.
ValentiniV., CocoC., CelliniN., PicciocchiA., RosettoM.E., MantiniG., MarmiroliL., BarbaroB., CogliandoloS., NuzzoG., TedescoM., Ambesi-ImpiombatoF., CosimelliM., RotmanM.: Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation.Int J Radiat Oncol Biol Phys,45: 1175–1184, 1999.
31.
StrykerS.J., KielK.D., RademakerA., ShawJ.M., UjikiG.T., PotichaS.M.: Preoperative chemoradiation for stages II and III rectal carcinoma.Arch Surg,131: 514–519, 1996.
32.
GrannA., MinskyB.D., CohenA.M., SaltzL., GuillemJ.G., PatyP.B., KelsenD.P., KemenyN., IlsonD., Bass-LoebJ.: Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin and concurrent radiation therapy for clinically resectable T3 rectal cancer.Dis Colon Rectum,40: 515–522, 1997.
